Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: A randomized phase III study

Annals of Oncology

Volumn 27, Issue 7, 2016, Pages 1235-1241

  Jacot, W ^a   Firmin, N ^a   Roca, L ^a   Topart, D ^b   Gallet, S ^a   Durigova, A ^a   Mirr, S ^a   Abach, L ^a   Pouderoux, S ^a   D'Hondt, V ^a   Bleuse, J P ^a   Lamy, P J ^a   Romieu, G ^a  

^a CENTRE VAL D AURELLE   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Chemotherapy; Early breast cancer; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; COLECALCIFEROL; 25-HYDROXYVITAMIN D; VITAMIN D;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CALCIUM URINE LEVEL; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MINERAL SUPPLEMENTATION; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ADULT; ADVERSE DRUG REACTION; AGED; ANALOGS AND DERIVATIVES; BLOOD; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; DIET THERAPY; DIETARY SUPPLEMENT; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BREAST NEOPLASMS; DIETARY SUPPLEMENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84977100599     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw145     Document Type: Article

References (23)

1. Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist 2008; 13: 187-195.
2. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18: 1570-1593.
3. Saarto T, Blomqvist C, Valimaki M et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997; 15: 1341-1347.
4. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19: 3306-3311.
5. Crew KD, Shane E, Cremers S et al. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 2009; 27: 2151-2156.
6. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among freeliving healthy young adults. Am J Med 2002; 112: 659-662.
7. Goodwin PJ, Ennis M, Pritchard KI et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27: 3757-3763.
8. Jacot W, Pouderoux S, Thezenas S et al. Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat 2012; 134: 709-717.
9. Mann GB, Kang YC, Brand C et al. Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. J Clin Oncol 2009; 27: 3605-3610.
10. Khan QJ, Reddy PS, Kimler BF et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119: 111-118.
11. Iqbal SJ. Vitamin D metabolism and the clinical aspects of measuring metabolites. Ann Clin Biochem 1994; 31(Pt 2): 109-124.
12. Holick MF. Noncalcemic actions of 1,25-dihydroxyvitamin D3 and clinical applications. Bone 1995; 17: 107S-111S.
13. Hollis BW. Assessment of vitamin D nutritional and hormonal status: what to measure and how to do it. Calcif Tissue Int 1996; 58: 4-5.
14. Van Poznak CH, Temin S, Yee GC et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29: 1221-1227.
15. Peppone LJ, Huston AJ, Reid ME et al. The effect of various vitamin D supplementation regimens in breast cancer patients. Breast Cancer Res Treat 2011; 127: 171-177.
16. Nogues X, Servitja S, Pena MJ et al. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. Maturitas 2010; 66: 291-297.
17. Roux C, Bischoff-Ferrari HA, Papapoulos SE et al. New insights into the role of vitamin D and calcium in osteoporosis management: an expert roundtable discussion. Curr Med Res Opin 2008; 24: 1363-1370.
18. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
19. Cavalier E, Delanaye P, Chapelle JP, Souberbielle JC. Vitamin D: current status and perspectives. Clin Chem Lab Med 2009; 47: 120-127.
20. Heaney RP, Davies KM, Chen TC et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204-210.
21. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007; 85: 6-18.
22. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999; 69: 842-856.
23. Prieto-Alhambra D, Javaid MK, Servitja S et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 2011; 125: 869-878.